Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Conditions

Neoplasm Metastasis 3Recurrence 2Prostatic Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Nephrotic Syndrome 1Kidney Diseases 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Diseases 1Familial Mediterranean Fever 1Fallopian Tube Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Arthritis, Rheumatoid 1Amyloidosis 1All Solid Tumors 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Pharmaceutical Preparations × Clear all
NCT01544322 2015-06-18

ME-344-001

MEI Pharma, Inc.

Phase 1 Completed
24 enrolled

Neoplasm Metastasis, Recurrence

NCT01401868 2013-06-24

Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

MEI Pharma, Inc.

Phase 1 Completed
18 enrolled

Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡